环丙沙星;Bay-09867 新品

＞98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

环丙沙星; Bay-09867

White to off white powder

0.1 M HCL : 16.67 mg/mL (50.31 mM; ultrasonic and warming and adjust pH to 2 with HCl and heat to 60°C)
H2O : < 0.1 mg/mL (insoluble)

Topoisomerase IV

Ciprofloxacin is a fluoroquinolone antibiotic, shows MIC90 (minimal inhibitory concentrations for 90%) of between 0.008 and 2 μg/ml for Enterobacteriaceae, Pseudomonas aeruginosa, Haemophilus influenzae, Neisseria gonorrhoeae, streptococci, Staphylococcus aureus, and Bacteroidesfragilis strains. Ciprofloxacin inhibits topoisomerase IV as a primary topoisomerase target and gyrase as a secondary target. Ciprofloxacin shows an AUC (area under the curve) of 24 μg×h/ml

Ciprofloxacin (1 mg/L) induces glutathione-S-transferase (GST) activity, in contrast with inhibited GST and Catalase (CAT) of larvae exposed to enrofloxacin. Ciprofloxacin (≥10 μg/L) and enrofloxacin are ecotoxic for development, growth, detoxifying, and oxidative stress enzymes in anuran amphibian larvae. In a murine model of pneumonic plague, Ciprofloxacin (30 mg/kg, i.p.) results in a drug exposure which is similar to the drug exposure observed in human following a 500 mg dose of oral Ciprofloxacin. Intraperitoneal Ciprofloxacin reduces the lung bacterial load compare to controls treated with intraperitoneal PBS.